Prenetics Launches $40 Million Share Repurchase Backed by $164M Liquidity
Prenetics’ Board approved a $40 million share repurchase program over 12 months, bringing total committed purchases by management and board to $42.75 million. The company holds $164 million in adjusted liquidity, zero debt, and expects its IM8 brand to generate $180–200 million in revenue with profitability by Q4 2027.
1. Share Repurchase Program Details
Prenetics’ Board authorized a $40 million share repurchase program over 12 months, allowing open‐market purchases, block trades and Rule 10b5-1 trading plans. Repurchases depend on price, market conditions and may be modified, suspended or discontinued at any time without notice.
2. Insider Investments Reinforce Conviction
Members of the executive leadership team have invested a cumulative $2.75 million of personal capital in Prenetics stock across two consecutive post-earnings trading windows, including CEO Danny Yeung’s $750,000 purchase at an average price of $17.11 per share.
3. Robust Balance Sheet and Divestitures
During 2025 and early 2026, Prenetics completed three strategic divestitures generating approximately $155 million gross proceeds, resulting in $164 million of total adjusted liquidity and zero debt as of March 1, 2026.
4. Growth Outlook and Profitability Path
Prenetics targets its IM8 brand to deliver $180–200 million in 2026 revenue and achieve adjusted EBITDA profitability by Q4 2027. At current valuations, enterprise value stands at about $89 million, implying significant upside if guidance is met.